Skip to main content
. 2020 Dec 15;12:12885–12894. doi: 10.2147/CMAR.S279684

Figure 4.

Figure 4

Nomogram to predict survival probability in ESCC patients receiving ACT. (A) Nomogram based on immunotype A (IS <1) and immunotype B (IS ≥1) and clinicopathological factors to predict two, three, and 5five-year survival in ESCC patients after ACT. Two-year (B), three-year (C) and five-year (D) nomogram evaluated by calibration curves. The dashed line represented an ideal evaluation, whereas the blue line represented the performance of the nomogram.